神州细胞 (688520)
Sinocelltech Group Limited
K-Line Chart
No K-line data available
Company NameBeijing Shenzhou Cell Biotechnology Group Co., Ltd.
Listing Date2020-06-22
Issue Price25.64RMB
Registered Capital44533.571410k RMB
Legal RepresentativeXie Liangzhi
Registered AddressRoom 307, Building 5, Yard 31, Ke Chuang Qi Street, Beijing Economic-Technological Development Area, Beijing
IndustryBiological Products
Main BusinessFocuses on the research, development, and industrialization of biopharmaceutical products such as monoclonal antibodies, recombinant proteins, and vaccines.
Company ProfileBeijing Shenzhou Cell Biotechnology Group Co., Ltd. is an innovative biopharmaceutical R&D company founded by Dr. Xie Liangzhi, an internationally renowned biopharmaceutical expert, one of China's first batch of "Thousand Talents Plan" experts, and a member of the 13th National Committee of the Chinese People's Political Consultative Conference. The company focuses on the research, development, and industrialization of biopharmaceutical products including monoclonal antibodies, recombinant proteins, vaccines, and cell therapies. For over a decade, the company has consistently dedicated itself to the R&D of macromolecular biotechnology and processes. It has now established an internationally leading, high-efficiency, and high-throughput technology platform covering the entire chain of biopharmaceutical R&D and production. Leveraging these technology platforms, the company is committed to developing high-quality, clinically competitive, and economically accessible biopharmaceutical products for patients. Simultaneously, the company strives to independently develop innovative biopharmaceutical products with internationally differentiated competitive advantages, aiming to bring its self-developed Best-in-Class biopharmaceuticals to the international market and establish a globally leading biopharmaceutical brand.
Stock Details
1. Key Indicators
- Total Shares(W): 44533.57
- Circulating A-Shares(W): 44533.57
- Earnings Per Share(RMB): -0.6000
- Net Assets Per Share(RMB): -1.6260
- Operating Revenue(W RMB): 131188.11
- Total Profit(W RMB): -25127.96
- **Net Profit Attributable to Parent(W RMB) **: -25067.23
- Net Profit Growth Rate(%): -267.17
- Weighted Return on Equity(%): -1491.8700
- Operating Cash Flow Per Share(RMB): -0.6890
- Undistributed Profit Per Share(RMB): -9.1730
- Capital Reserve Per Share(RMB): 6.5479
2. Main Business
The main business covers:
- Research, development and industrialization of biopharmaceutical products including monoclonal antibodies, recombinant proteins and vaccines
- Research, development and industrialization of biopharmaceutical products for multiple therapeutic and preventive areas including malignant tumors, autoimmune diseases, infectious diseases and genetic diseases
3. Company Basic Information
- Company Name: Beijing Sinocelltech Ltd.
- Listing Date: 2020-06-22
- Industry: Pharmaceutical Manufacturing
- Address: Room 307, Building 5, No. 31 Yard, Ke Chuang 7th Street, Beijing Economic-Technological Development Area, Beijing
- Website: https://www.sinocelltech.com
- Company Profile: Beijing Sinocelltech Ltd. is a company focusing on the research, development and industrialization of biopharmaceutical products, mainly involving monoclonal antibodies, recombinant proteins and vaccines, covering multiple therapeutic and preventive areas including malignant tumors, autoimmune diseases, infectious diseases and genetic diseases.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Lhasa Ailik Investment Consulting Co., Ltd. | General Legal Person | 27121.28 | 60.90 |
| 2 | Nanchang Sinocell Anyuan Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 2039.48 | 4.58 |
| 3 | Lhasa Lianghaoyuan Investment Consulting Co., Ltd. | General Legal Person | 2000.60 | 4.49 |
| 4 | Nanchang Sinocell Anheng Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 715.72 | 1.61 |
| 5 | Hong Kong Securities Clearing Company Ltd. | Northbound Capital | 461.68 | 1.04 |
| 6 | CSI 500 Exchange Traded Fund | Fund | 260.91 | 0.59 |
| 7 | Anyi Sinocell Ancheng Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 180.25 | 0.40 |
| 8 | Anyi Sinocell Anqian Enterprise Management Consulting Partnership (Limited Partnership) | General Legal Person | 179.97 | 0.40 |
| 9 | Yinhua CSI Innovative Pharmaceutical Industry Exchange Traded Fund | Fund | 178.93 | 0.40 |
| 10 | Qianhai Open Source Refinancing Theme Selected Stock Securities Investment Fund | Fund | 34.68 | 0.08 |
5. Concept Sectors
- Biological Vaccines
- Gene Concept
- Baidu Concept
- Innovative Drugs
- Margin Trading & Securities Lending
- Private Placement Plan
- Risk Warning
- Low Safety Score
- Small Cap Growth
- SZSE Growth
- STAR Market Biotech
- SZSE Emerging Index
- STAR Market 100
Remarks
- Data update date: 2025-11-07
- Data source: Public Market Information